Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding‐ clinically relevant non‐major Treatment duration 28 ‐ 42… compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Anticoagulants (chosen at investigators' discretion) showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (low certainty).
1 finding from 1 review
Major bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin showed no clear difference in bleeding ‐ major Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin leads to higher bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in symptomatic PE Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Total VTE · people requiring prevention of venous thromboembolism
Fondaparinux probably leads to lower total VTE compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · people requiring prevention of venous thromboembolism
Fondaparinux leads to lower symptomatic VTE compared with placebo (high certainty).
1 finding from 1 review